Free Trial
NASDAQ:EVAX

Evaxion A/S Q3 2023 Earnings Report

Evaxion A/S logo
$2.66 +0.00 (+0.11%)
As of 12:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evaxion A/S EPS Results

Actual EPS
-$10.50
Consensus EPS
-$9.50
Beat/Miss
Missed by -$1.00
One Year Ago EPS
N/A

Evaxion A/S Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evaxion A/S Announcement Details

Quarter
Q3 2023
Time
Q3 2023 Earnings Release
Conference Call Date
Tuesday, December 19, 2023
Conference Call Time
2:00AM ET

Upcoming Earnings

Evaxion A/S' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Evaxion A/S Earnings Headlines

Evaxion A/S (NASDAQ:EVAX) Trading 3.1% Higher - Here's What Happened
The Next Commodity Crisis Just Got a Name: Silver
Elon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to SpaceX to AI. And now, whispers are growing that his next move could be in silver. Why? Because silver is the lifeblood of EVs, solar panels, and AI tech.
Evaxion CEO Departs; CFO and Interim CEO Appointed
See More Evaxion A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evaxion A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evaxion A/S and other key companies, straight to your email.

About Evaxion A/S

Evaxion A/S (NASDAQ:EVAX) is a clinical‐stage biotechnology company focused on harnessing artificial intelligence to develop novel immunotherapies. Headquartered in Copenhagen, Denmark, the company leverages its proprietary AI‐powered platforms to design precision vaccines and therapeutic candidates targeting both oncology and infectious diseases. Evaxion’s approach integrates computational algorithms with advanced immunology to accelerate the discovery and optimization of immunogenic peptides capable of triggering robust immune responses.

The company’s core offering is its PIONEER™ drug discovery platform, which utilizes machine learning and deep sequencing data to predict and validate epitopes that can be formulated into vaccines or biologics. Evaxion has built a diverse pipeline of preclinical and clinical‐stage products, including personalized cancer vaccines aimed at neoantigens in solid tumors and preventive vaccines for emerging infectious threats. By combining in silico design with in vitro and in vivo validation, Evaxion seeks to reduce development timelines and increase the likelihood of clinical success.

Founded in 2017 as a spin‐out from Danish academic institutions, Evaxion has grown to serve a global market, collaborating with leading research centers and pharmaceutical partners in Europe and the United States. The company’s research programs encompass areas such as melanoma, non‐small cell lung cancer, and neglected tropical diseases. Over time, Evaxion has secured strategic alliances to advance its clinical trials and expand manufacturing capabilities, positioning itself as an innovator in the field of AI‐driven immunotherapy.

Evaxion’s leadership team combines expertise in computational biology, immuno‐oncology, and pharmaceutical development. The executive management and scientific advisory board include seasoned professionals with backgrounds in biostatistics, molecular immunology, and regulatory affairs. Under this multidisciplinary leadership, Evaxion continues to refine its AI platforms and drive multiple collaborative programs toward clinical milestones, aiming to deliver first‐in‐class therapeutics that address critical unmet needs in cancer and infectious disease treatment.

View Evaxion A/S Profile

More Earnings Resources from MarketBeat